Can-Fite BioPharma Announces Patient With Advanced Decompensated Liver Cirrhosis Underwent Liver Transplantation Following Treatment With Namodenoson

Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure

Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson subsequently underwent a successful liver transplantation.

The patient received Namodenoson treatment under a compassionate use framework while suffering from liver disease and complications consistent with decompensated cirrhosis. Throughout the treatment period, Namodenoson contributed to clinical stabilization, allowing the patient to remain a suitable candidate for liver transplantation until a compatible donor organ became available, ultimately resulting in a successful, life-saving liver transplantation. While this is a single case, the outcome suggests a potential supportive role for Namodenoson in patients with severe liver dysfunction awaiting transplantation. Due to the ongoing shortage of donor organs, many patients with decompensated cirrhosis deteriorate rapidly and, tragically, do not survive long enough to receive a suitable transplant, highlighting the importance of therapies that may help maintain stability during this critical period.

Namodenoson is an orally bioavailable A3 adenosine receptor (A3AR) agonist with anti-inflammatory and anti-fibrotic properties, which has demonstrated a favourable safety profile in previous clinical studies. The drug is currently being evaluated in advanced liver diseases, including MASH and hepatocellular carcinoma.